GlassScriptPhysician profile
Danielle Marie Leivian
NPI 1194954081
$726.66
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $87.91 · 2021: $246.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $126.88 | 2019-2021 | |
| Adlon Therapeutics L.P. | $112.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.31 | 2019-2021 | |
| Pfizer INC. | $73.00 | 2019 | |
| Shire North American Group INC | $46.69 | 2019 | |
| Ironshore Pharmaceuticals INC. | $45.05 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $43.92 | 2019 | |
| Tris Pharma INC | $39.85 | 2019 | |
| Glaxosmithkline, LLC. | $25.72 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $17.44 | 2021 | |
| Abbvie INC. | $16.89 | 2021 | |
| Merck Sharp & Dohme LLC | $13.36 | 2020 | |
| Mylan Pharmaceuticals INC. | $13.33 | 2019 | |
| Sanofi Pasteur INC. | $12.95 | 2021 | |
| Biogen, INC. | $12.77 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $11.69 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Leivian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.